Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: iCAD Inc

Market Cap 106M 91.2M 84.04M 78.67M 147M 10.04B 150M 992M 387M 4.89B 396M 388M 16.92B P/E Ratio 2023
-9.35x
P/E Ratio 2024 -8.59x
Enterprise Value 88.75M 76.65M 70.64M 66.12M 124M 8.44B 126M 834M 325M 4.11B 333M 326M 14.22B EV / Sales 2023
1.47x
EV / Sales 2024 1.6x
Free-Float
99.32%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer 61 10/03/2023
Director of Finance/CFO 54 17/07/2025
Corporate Secretary - 17/07/2025
Change 5-day change 1-year change 3-year change Capi.($)
-1.01%-0.45%+13.33%-10.12% 177B
-1.50%-3.80%-20.85%+29.46% 146B
-0.11%-2.02%-11.96%-24.14% 128B
-1.04%-4.20%-52.81%-9.16% 70.11B
-1.28%-1.72%+11.32%-1.27% 49.38B
+0.67%-0.60%-25.38%-34.31% 44.23B
-0.36%-4.62%+8.64%+8.98% 36.59B
-1.08%-2.51%+1.89%+38.63% 35.32B
+0.51%+0.05%-11.50%-17.34% 29.35B
Average -0.63%-2.17%-9.70%-2.14% 79.55B
Weighted average by Cap. -0.82%-2.08%-9.00%-2.25%

Financials

2023 2024
Net sales 17.32M 14.96M 13.78M 12.9M 24.18M 1.65B 24.55M 163M 63.45M 801M 64.99M 63.61M 2.77B 19.61M 16.94M 15.61M 14.61M 27.38M 1.86B 27.8M 184M 71.85M 907M 73.59M 72.02M 3.14B
Net income -4.85M -4.19M -3.86M -3.61M -6.77M -461M -6.87M -45.55M -17.76M -224M -18.19M -17.8M -776M -5.62M -4.85M -4.47M -4.18M -7.84M -534M -7.96M -52.78M -20.58M -260M -21.08M -20.63M -900M
Net Debt -21.21M -18.32M -16.88M -15.8M -29.61M -2.02B -30.07M -199M -77.71M -981M -79.6M -77.9M -3.4B -16.84M -14.55M -13.41M -12.55M -23.52M -1.6B -23.88M -158M -61.72M -779M -63.22M -61.87M -2.7B
Logo iCAD Inc
iCAD Inc is a United States‑based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AI‑driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.
Employees
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!